Eymen Gümüşdil

Eymen Gümüşdil

Auto-generated profile, based on publicly available information

Eymen Gümüşdil

German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YHYongqi Huang
Yongqi Huang
JWJitao Wen
Jitao Wen
LRLisa-Marie Ramirez
Lisa-Marie Ramirez
EGEymen Gümüşdil
Eymen Gümüşdil
PPPravin Pokhrel
Pravin Pokhrel
MGMeng Gao
Meng Gao
Preventing tau aggregation is a potential therapeutic strategy in Alzheimer’s disease and other tauopathies. Recently, liquid–liquid phase separation has been found to facilitate the formation of pathogenic tau conformations and fibrillar aggregates, although many aspects of the conformational transitions of tau during the phase transition process remain unknown. Here, we demonstrate that the tau aggregation inhibitor methylene blue promotes tau liquid–liquid phase separation and accelerates the liquid-to-gel transition of tau droplets independent of the redox activity of methylene blue. We further show that methylene blue inhibits the conversion of tau droplets into fibrils and reduces the cytotoxicity of tau aggregates. Although gelation slows down the mobility of tau and tubulin, it does not impair microtubule assembly within tau droplets. These findings suggest that methylene blue inhibits tau amyloid fibrillization and accelerates tau droplet gelation via distinct mechanisms, thus providing insights into the activity of tau aggregation inhibitors in the context of phase transition.